By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Protalix Biotherapeutics, Inc. 

2 Snunit St.
Science Park
Carmiel      Israel
Phone: 972-4-9028100 Fax: 972-4-988-9489


SEARCH JOBS


Industry
Biotechnology

Segment
Biotechnology





Company News
Protalix Biotherapeutics, Inc. (PLX) Reports 2017 Second Quarter Results and Provides Corporate Update 8/9/2017 1:03:55 PM
Protalix Biotherapeutics, Inc. (PLX) Announces FDA Approval To Operate Its Current Facility As A Multi-Product Facility 6/1/2017 11:04:16 AM
Protalix Biotherapeutics, Inc. (PLX) Reports 2017 First Quarter Results and Provides Corporate Update 5/10/2017 10:44:12 AM
Protalix Biotherapeutics, Inc. (PLX) To Hold First Quarter 2017 Financial Results And Corporate Update Conference Call On May 10, 2017 5/1/2017 10:49:12 AM
Protalix Biotherapeutics, Inc. (PLX) Announces Positive Results From Phase II Clinical Trial Of Alidornase Alfa (AIR Dnase) For The Treatment Of Cystic Fibrosis 4/12/2017 10:22:33 AM
Protalix Biotherapeutics, Inc. (PLX) Announces Additional Positive Data From Its Phase I/II Clinical Trial For PRX-102 For The Treatment Of Fabry Disease 8/10/2016 7:55:34 AM
Protalix Biotherapeutics, Inc. (PLX) Reports Fiscal Year 2015 Financial Results And Provides Corporate Update 3/8/2016 8:21:30 AM
Protalix Biotherapeutics, Inc. (PLX) Presents Positive Six And Twelve Month Interim Clinical Data On PRX-102 For The Treatment Of Fabry Disease At The 12th Annual Worldsymposium 2016 3/3/2016 7:43:05 AM
Protalix Biotherapeutics, Inc. (PLX) To Participate In The Suntrust Robinson Humphrey Orphan Drug Day And The 12th Annual Worldsymposium 2016 2/22/2016 11:56:03 AM
Protalix Biotherapeutics, Inc. (PLX) To Conduct Phase III Clinical Trial For PRX-102 For The Treatment Of Fabry Disease Following A Successful End-Of-Phase II Meeting With FDA 11/16/2015 7:42:07 AM
123
//-->